Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04256018 · ClinicalTrials.gov registry record · Phase 2
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
A Phase 2 study of Mycosis Fungoides and Sezary Syndrome, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04256018 is a Phase 2 study of Mycosis Fungoides and Sezary Syndrome that is actively recruiting participants, run by Stanford University. The registered enrollment target is 30 participants, below the 162-participant average among 19 other Mycosis Fungoides trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04256018, a Phase 2 study of Mycosis Fungoides and Sezary Syndrome, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the efficacy of the combination of LD-TSEBT and mogamulizumab in patients with MF and SS. And to evaluate the secondary measures of clinical benefit of the combination therapy and to evaluate the safety and tolerability of the combination in patients with MF and SS.
Conditions Studied
Interventions
- DRUG Mogamulizumab
- RADIATION LD TSEBT
Study Locations (1)
California
- Stanford Cancer Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-03-30 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04256018
The ClinicalTrials.gov registry entry for NCT04256018 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 162-participant average among 19 other Mycosis Fungoides trials with a reported enrollment target (81% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mycosis Fungoides appearing as the primary indexed condition, and to 2 interventions - of which Mogamulizumab is the first listed.
NCT04256018 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04256018 about?
NCT04256018 is a clinical study titled "Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome". The purpose of this study is to determine the efficacy of the combination of LD-TSEBT and mogamulizumab in patients with MF and SS. And to evaluate the secondary measures of clinical benefit of the combination therapy and to evaluate the safety and tolerability of the combination in patients with MF...
What is the current status of trial NCT04256018?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2020-03-30. Estimated completion is 2026-12.
What conditions does trial NCT04256018 study?
This clinical trial studies the following conditions: Mycosis Fungoides, Sezary Syndrome.
What interventions are being tested in trial NCT04256018?
The interventions under investigation include: Mogamulizumab (DRUG), LD TSEBT (RADIATION).
Who is sponsoring clinical trial NCT04256018?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04256018 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mycosis Fungoides
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Photopheresis in Early-stage Mycosis Fungoides
RECRUITING · Phase 2
-
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
RECRUITING · Phase 2
-
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
RECRUITING · Phase 2
-
Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides
RECRUITING · Phase 2
-
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.